
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Design Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

25056L103

(CUSIP Number)

Derek Gould
One Letterman Drive, Building C, Suite C3
San Francisco, CA, 94129
(415) 801-4660

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/07/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 25056L103

Name of reporting person

1

Logos Global Management LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only
Source of funds (See Instructions)

4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE
Sole Voting Power

7 0.00
Number of Shares Beneficially Owned by Each Reporting Person

8 3,240,000.00
Shared Voting Power

9 0.00
Sole Dispositive Power

10 3,240,000.00
Shared Dispositive Power
Aggregate amount beneficially owned by each reporting person

11 3,240,000.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 5.7 %
Type of Reporting Person (See Instructions)

14 IA, PN

Comment for Type of Reporting Person: Percentage based on 56,963,757 shares of Common Stock outstanding as of October 31, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2025.

SCHEDULE 13D

CUSIP No. 25056L103

1 Name of reporting person
Logos Global Management GP LLC
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

Number of Shares

0.00 Shared Voting Power

Beneficially

8 3,240,000.00

Owned by

Each

Sole Dispositive Power

Reporting

9 0.00

Person

With:

Shared Dispositive Power

10

3,240,000.00

Aggregate amount beneficially owned by each reporting person

11 3,240,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13 5.7 %

Type of Reporting Person (See Instructions)

14 HC, OO

Comment for Type of Reporting Person: Percentage based on 56,963,757 shares of Common Stock outstanding as of October 31, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2025.

SCHEDULE 13D

CUSIP No. 25056L103

Name of reporting person

1 Logos Global Master Fund LP

Check the appropriate box if a member of a Group (See Instructions)

2 (a)

(b)

3 SEC use only

Source of funds (See Instructions)

4 WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6 DELAWARE

Sole Voting Power

Number of Shares

7

Beneficially

0.00

Owned by

Each

Shared Voting Power

Reporting

8 2,240,000.00

Person

With:

Sole Dispositive Power

9

0.00

10 Shared Dispositive Power

2,240,000.00

Aggregate amount beneficially owned by each reporting person

11

2,240,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

3.9 %

Type of Reporting Person (See Instructions)

14

PN

Comment for Type of Reporting Person: Percentage based on 56,963,757 shares of Common Stock outstanding as of October 31, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2025.

SCHEDULE 13D

CUSIP No. 25056L103

Name of reporting person

1

Logos GP LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

0.00

Number of
Shares

Shared Voting Power

Beneficially
Owned by

8

2,240,000.00

Each
Reporting

9

Sole Dispositive Power

Person
With:

0.00

Shared Dispositive Power

10

2,240,000.00

Aggregate amount beneficially owned by each reporting person

11

2,240,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

3.9 %

14 Type of Reporting Person (See Instructions)

HC, OO

Comment for Type of Reporting Person: Percentage based on 56,963,757 shares of Common Stock outstanding as of October 31, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2025.

SCHEDULE 13D

CUSIP No. 25056L103

Name of reporting person

1

Arsani William

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

UNITED STATES

Sole Voting Power

7

15,000.00

Number of Shares Beneficially

Shared Voting Power

Owned by

8 3,240,000.00

Each Reporting Person

Sole Dispositive Power

9

15,000.00

With:

Shared Dispositive Power

10

3,240,000.00

Aggregate amount beneficially owned by each reporting person

11

3,255,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

5.7 %

Type of Reporting Person (See Instructions)

14

IN, HC

Comment for Type of Reporting Person: Percentage based on 56,963,757 shares of Common Stock outstanding as of October 31, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2025.

SCHEDULE 13D

Item 1. Security and Issuer
Title of Class of Securities:

(a) Common Stock
Name of Issuer:

(b) Design Therapeutics, Inc.
Address of Issuer's Principal Executive Offices:

(c) 6005 Hidden Valley Road, Suite 110, Carlsbad, CALIFORNIA , 92011.

Item 2. Identity and Background

(a) The reporting persons are: Logos Global Management LP, a Delaware limited partnership ("Logos Global") Logos Global Management GP LLC, a Delaware limited liability company ("Logos Global GP") Logos Global Master Fund LP, a Delaware limited partnership ("Global Fund") Logos GP LLC, a Delaware limited liability company ("Logos GP") Arsani William The reporting persons are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. Each reporting person disclaims beneficial ownership of Stock except to the extent of that person's pecuniary interest therein.

(b) One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129.

(c) Logos Global is the investment adviser to several private funds, including Global Fund (collectively, the "Funds"). Logos Global GP is the general partner of Logos Global. Logos GP is the general partner of Global Fund. Dr. William is the control person of Logos Global, Logos Global GP and Logos GP and the portfolio manager of Global Fund.

(d) During the last five years, none of the reporting persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, none of the reporting persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) For citizenship of the reporting persons, see Item 6 of each reporting person's cover page.

Item 3. Source and Amount of Funds or Other Consideration

Certain of the Funds acquired 1,217,627 shares of the Stock as a result of the automatic conversion of shares of Preferred Stock of the Issuer immediately prior to the completion of the Issuer's initial public offering on March 30, 2021. No additional consideration was paid for those shares of Stock. Dr. William was granted options to acquire 15,000 shares of the Stock for his services as a director. The shares of Stock held by Global Fund were acquired for a total purchase price of \$5,503,042. The Funds used their working capital to make the foregoing purchases.

Item 4. Purpose of Transaction

The reporting persons filed this Schedule 13D because Dr. William was on the Issuer's board of directors. Dr. William has resigned from the Issuer's board of directors on September 9, 2025. The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations. Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time. Such actions may include purchasing additional securities in the open market, through privately negotiated transactions with third parties or otherwise, and selling at any time, in the open market, through privately negotiated transactions with third parties or otherwise, all or part of the securities now owned or hereafter acquired by any of them. The reporting persons also may from time to time enter into or unwind hedging or other derivative transactions with respect to the Stock or pledge their interests in the Stock to obtain liquidity. In addition, from time to time the reporting persons and their representatives and advisers may communicate with other stockholders, industry participants and other interested parties about the Issuer. The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act. However, the reporting persons may recommend additional actions to the Issuer's management, board of directors and stockholders. Any such actions could involve one or more of the events referred to in clauses (a) through (j) of Item 4 of Schedule 13D, including, potentially, one or more mergers, consolidations, sales or acquisitions of assets, change in control, issuances, purchases, dispositions or pledges of securities or other changes in capitalization.

Item 5. Interest in Securities of the Issuer

(a) Aggregate number of shares beneficially owned by the reporting persons: Logos Global: 3,240,000 Logos Global GP: 3,240,000 Global Fund: 2,240,000 Logos GP: 2,240,000 Arsani William: 3,255,000 Aggregate percentage of the class of Stock beneficially owned by the reporting persons: Logos Global: 5.7% Logos Global GP: 5.7% Global Fund: 3.9% Logos GP: 3.9% Arsani William: 5.7%

(b) Number of shares as to which the each reporting person has: (i) Sole power to vote or to direct the vote: Logos Global: 0 Logos Global GP: 0 Global Fund: 0 Logos GP: 0 Arsani William: 15,000 (ii) Shared power to vote or to direct the vote: Logos Global: 3,240,000 Logos Global GP: 3,240,000 Global Fund: 2,240,000 Logos GP: 2,240,000 Arsani William: 3,240,000 (iii) Sole power to dispose or to direct the disposition of: Logos Global: 0 Logos Global

GP: 0 Global Fund: 0 Logos GP: 0 Arsani William: 15,000 (iv) Shared power to dispose or to direct the disposition of: Logos Global: 3,240,000 Logos Global GP: 3,240,000 Global Fund: 2,240,000 Logos GP: 2,240,000 Arsani William: 3,240,000

- (c) The reporting persons engaged in the transactions set forth on Exhibit 99.2 in the Issuer's Common Stock in the 60 days preceding the date of this Schedule 13D. All transactions were effectuated in the open market through a broker.
- (d) Not applicable.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Logos Global is the investment adviser to its clients pursuant to investment management agreements or limited partnership agreements providing to Logos Global the authority, among other things, to invest the funds of such clients in Stock, to vote and dispose of Stock and to file this statement on behalf of such clients. Pursuant to such limited partnership agreements, Logos Global and its affiliates are entitled to allocations based on assets under management and realized and unrealized gains. Pursuant to such investment management agreements, Logos Global is entitled to fees based on assets under management and realized and unrealized gains.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.1 Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. Exhibit 99.2 Transactions in the Past 60 Days

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Logos Global Management LP

Signature: /s/ Arsani William

Name/Title: Managing Partner

Date: 11/12/2025

Logos Global Management GP LLC

Signature: /s/ Arsani William

Name/Title: Managing Member

Date: 11/12/2025

Logos Global Master Fund LP

Signature: /s/ Arsani William

Name/Title: Managing Member of Logos GP LLC, General Partner of Logos Global Master Fund LP

Date: 11/12/2025

Logos GP LLC

Signature: /s/ Arsani William

Name/Title: Managing Member

Date: 11/12/2025

Arsani William

Signature: /s/ Arsani William

Name/Title: Self Reporting

Date: 11/12/2025

EXHIBIT A

AGREEMENT REGARDING JOINT FILING
OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Logos Global Management LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

Dated: November 12, 2025

Logos Global Management LP

Signature: /s/ Arsani William
Name/Title: Managing Partner

Logos Global Management GP LLC

Signature: /s/ Arsani William
Name/Title: Managing Member

/s/ Arsani William
Arsani William

Logos Global Master Fund LP

Signature: /s/ Arsani William
Name/Title: Managing Member of Logos GP LLC, General Partner
of Logos Global Master Fund LP

Logos GP LLC

Signature: /s/ Arsani William
Name/Title: Managing Member

EXHIBIT 99.2

TRANSACTIONS IN THE PAST 60 DAYS

The reporting persons engaged in the following open market transactions in the Issuer's Common Stock in the 60 days preceding the filing of this Schedule 13D.

Date	Fund	Purchase or Sale	Number of Shares	Price per Share
11/7/2025	Logos Global Master Fund, L.P.	Sale	(415,000)	\$7.25